2nd Quarter - Amendment
NEUROCRINE BIOSCIENCES, INC for NEUROCRINE BIOSCIENCES, INC
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2020 | $440,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Jul 20, 2020 | $440,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act. S.2543 Prescription Drug Pricing Reduction Act of 2019. Structure and reimbursement for Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID BOYER | Sp. Ast. Pres LA, Ast Com Leg, FDA; Sp Ast Sec HHS, Con Asst, Off of WH Liaison DOD, Con Asst, Off of Sec Lab. |
| TIMOTHY CLARK | — |
Health Issues HCR
Regulatory and legislative health care issues impacting pricing and access; Diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinsons Disease
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.